Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | DRD5 | P21918 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6337190 | 1.00 | SMYD2 (0.35) | SMYD2AKR1C3CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL6337193 | 1.00 | SMYD2 (0.35) | SMYD2AKR1C3CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL6423008 | 1.00 | SMYD2 (0.35) | SMYD2AKR1C3CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL6337191 | 1.00 | SMYD2 (0.35) | SMYD2AKR1C3CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL6345134 | 0.80 | SMYD2 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2DRD2 | |
| SCHEMBL6345131 | 0.80 | SMYD2 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2DRD2 | |
| SCHEMBL5463435 | 0.80 | SMYD2 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2DRD2 | |
| SCHEMBL5463430 | 0.80 | SMYD2 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2DRD2 | |
| SCHEMBL5463439 | 0.80 | SMYD2 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2DRD2 | |
| SCHEMBL30558125 | 0.77 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203144-A1 | Bicyclo[3.1.0]hexane containing oxazolidinone antibiotics and derivatives thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-09-15 | — | — | US | disclosed |
| EP-1385834-B1 | BICYCLO[3,1,0]HEXANE CONTAINING OXAZOLIDINONE ANTIBIOTIC AND DERIVATIVES THEREOF | MERCK & CO INC (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1385834-A1 | BICYCLO[3,1,0]HEXANE CONTAINING OXAZOLIDINONE ANTIBIOTIC AND DERIVATIVES THEREOF | Merck & Co., Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2003027083-A1 | BICYCLO[3,1,0]HEXANE CONTAINING OXAZOLIDINONE ANTIBIOTIC AND DERIVATIVES THEREOF | MERCK & CO., INC. (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203144-A1 | Bicyclo[3.1.0]hexane containing oxazolidinone antibiotics and derivatives thereof | NR0B1, NR4A1, VDR | SMYD2 4868/4885AKR1C3 298/4885CYP3A4 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.